CION Ameerpet
A few ovarian tumours are fed by oestrogen the way a fire is fed by air. For those — mainly low-grade serous carcinoma and the hormone-producing stromal tumours — a tablet that shuts the oestrogen supply down can hold the disease still for a long time. For high-grade serous cancer, which is the common kind, it does much less. This page draws that line honestly, because being offered the wrong treatment gently is still being offered the wrong treatment.
Search hormone therapy ovarian cancer and two opposite things come back wearing the same name. One is hormone replacement, given after the ovaries are removed to settle menopausal symptoms — that adds oestrogen. The other, which is what this page is about, takes oestrogen away, because a minority of ovarian tumours use it to grow. They are not two versions of one idea. They pull in opposite directions, and it is worth knowing which one your doctor meant.
Some ovarian tumour cells carry oestrogen receptors on their surface. Oestrogen docks there and tells the cell to divide. Anti-hormone treatment interrupts that conversation in one of three ways. The aromatase-inhibitor class blocks the enzyme that makes oestrogen in fat and muscle tissue, which after the menopause is where nearly all of it comes from. The selective oestrogen-receptor modulator (SERM) class sits in the receptor itself so oestrogen cannot. And where a woman still has working ovaries, a GnRH-agonist-class injection switches them off, because a tablet alone cannot outpace an ovary that is still producing.
In practice it is one tablet a day, taken at home, with a clinic visit and a CA-125 every couple of months and a scan every few. There is no cannula, no day-care unit and no hair loss. What there is instead is patience: hormone therapy rarely makes a tumour shrink dramatically. It holds it still, and in the slow-growing tumours where it is used, still can mean months or years. Where it sits among the other options is set out in our guide to ovarian cancer treatment in Hyderabad.
The target is oestrogen, not the dividing cell. Nothing is being poisoned, so the effects are menopausal ones — flushes, stiff joints, thinning bone — rather than low counts and hair loss.
Once daily, long term, with clinic reviews spaced months apart. For many women that difference in daily life is the whole point of choosing it.
Success here usually looks like a scan that has not changed and a CA-125 that has stopped climbing, not a tumour that has disappeared.
Hormone therapy is not a fringe idea in low-grade serous carcinoma — it is one of the better-supported options in a tumour that responds poorly to chemotherapy. In a large single-centre analysis, women with low-grade serous cancer of the ovary or peritoneum who took hormonal maintenance after surgery and chemotherapy went a median of 64.9 months before the disease progressed, compared with 26.4 months for those who were observed. That study was retrospective rather than randomised, so it cannot settle the question on its own — but the size of the gap is why hormonal maintenance now appears as an accepted option in international guidelines for this subtype. Source: Gershenson DM et al., Journal of Clinical Oncology (2017); NCCN Ovarian Cancer guidelines.
Ovarian cancer is not one disease, and hormone therapy is not a general treatment for it. There are a small number of situations where it is genuinely one of the better choices, and a much larger number where it is not. Here is the honest map.
Low-grade serous carcinoma behaves nothing like the common high-grade kind. It grows slowly, it is diagnosed at a younger average age, it almost always carries oestrogen receptors, and — the part that changes everything — it responds poorly to chemotherapy. When a tumour is both slow and chemotherapy-resistant, a treatment that quietly holds it in place for years is worth more than one that shrinks it briefly and costs you your hair.
So hormone therapy is used here in two places: as maintenance after surgery and chemotherapy, to lengthen the time before anything comes back, and as treatment in its own right when disease does recur. Much of the searching for hormone therapy ovarian cancer is done by women in exactly this position. There is more on the subtype itself in our guide to low-grade serous ovarian carcinoma.
These tumours arise from the hormone-producing tissue of the ovary rather than from its surface lining. They make oestrogen, which is often how they announce themselves — post-menopausal bleeding, or a thickened womb lining found on a scan done for something else. They also carry oestrogen and progesterone receptors, which makes them a logical target for anti-hormone treatment.
Surgery is the mainstay, and most adult granulosa cell tumours are found early and do well. The place for hormone therapy is recurrence, which in this tumour can appear many years later. It is used there because it is often effective, and because the alternative — repeated chemotherapy for a disease that may come back slowly over decades — is a hard bargain. See our guide to the granulosa cell tumour.
There is a third group: women with high-grade disease that has come back slowly, is low in volume, is causing few symptoms, and is receptor-positive on the original pathology. Here hormone therapy is sometimes used as a holding measure — not because it works as well as chemotherapy, but because it may keep things quiet for a while and let the body, and the person, recover before the next line of treatment.
This is a judgement made with you rather than for you, and it should be made with clear eyes. It needs scans and CA-125 checked on time, and an agreed plan for switching if the disease starts moving. A holding treatment is only reasonable while it is holding.
High-grade serous carcinoma is the commonest ovarian cancer, and it is the one most women reading about ovarian cancer actually have. It frequently stains positive for oestrogen receptors, which is why the question keeps coming up. But it grows fast and it is driven by genomic instability rather than by hormone signalling, and hormone therapy produces few meaningful responses in it.
For newly diagnosed high-grade disease the plan is surgery and platinum-based chemotherapy, with maintenance chosen on BRCA and HRD results. Substituting a hormone tablet for that would be a poor trade. If you want the whole treatment landscape in one place, start with our complete guide to ovarian cancer.
The aromatase-inhibitor class only works properly once the ovaries have stopped producing oestrogen. In a woman whose ovaries are still working, blocking the enzyme in fat and muscle simply prompts the ovary to produce more, and the treatment fails. This is a common and avoidable mistake.
The ways around it are straightforward: ovarian suppression with a GnRH-agonist-class injection alongside the tablet, or a SERM-class tablet instead, which blocks the receptor and does not depend on menopausal status. If both ovaries have already been removed, the question does not arise. Either way it is a conversation to have before the first prescription, not after the first scan.
If your pathology report mentions ER or PR with a percentage, that is receptor staining on the tumour. A receptor-negative result is genuinely useful: it makes hormone therapy very unlikely to help, and it saves you months of a treatment that was never going to work.
A positive result is weaker evidence than most people assume. In breast cancer, receptor status predicts response reasonably well. In ovarian cancer it does not, and plenty of receptor-positive ovarian tumours simply do not respond. That is why the tumour type — low-grade serous, stromal, high-grade — carries more weight in this decision than the percentage on the report does.
Most women tolerate hormone therapy well, but it is not free of effects, and a few of them are worth reporting the same week rather than at the next review.
On SERM-class treatment the lining of the womb can thicken. Any bleeding after the menopause needs assessment, usually a simple scan. Do not wait for the next appointment.
The SERM class carries a small increase in clot risk. These symptoms need same-day assessment, and a clot is very treatable when it is caught early.
Common on the aromatase-inhibitor class, worst in the mornings, and often manageable with simple measures or a change of agent within the class. Say so rather than quietly stopping the tablet.
Long-term oestrogen blockade thins bone. This is what the DEXA scan is for, and bone-protecting treatment can be added.
Flushes and vaginal dryness are the usual price of this treatment. There are non-hormonal options for both, so be honest about how bad it is — treatment you stop taking helps nobody.
Hormone therapy holds slow disease. Symptoms that are clearly progressing are a reason to scan early rather than wait for the calendar.
Never stop the tablet on your own because of side effects. Almost every problem on this list has an answer, and stopping without telling anyone means the next scan gets read as treatment failure when it was nothing of the kind.
Bring your pathology report — particularly the tumour type and any receptor staining — your last scan and your CA-125 values. In 45 minutes a medical oncologist can tell you whether hormone therapy is a realistic option for your tumour, or whether it would only delay treatment that works better.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If your tumour type is one hormone therapy rarely helps, we will say so plainly rather than prescribe it because it is easy to take.
Which class you are offered depends on your tumour type, whether you have been through the menopause, and what your bones and clotting history allow. This is the comparison that rarely fits into a ten-minute appointment.
| Drug class | Where it is used in ovarian cancer | What it asks of you |
|---|---|---|
| Aromatase-inhibitor class | The usual first choice in low-grade serous carcinoma, as maintenance or at recurrence, and in recurrent stromal tumours. Works only after the menopause, or with the ovaries suppressed. | A daily tablet. Hot flushes, joint stiffness and vaginal dryness are common; bone density falls over years, so a DEXA scan, calcium and vitamin D go with it. |
| Selective oestrogen-receptor modulator (SERM) class | An alternative where the aromatase-inhibitor class is unsuitable, and usable before the menopause because it does not depend on the ovaries shutting down. | A daily tablet. Hot flushes, a small increase in clot risk, and thickening of the womb lining — so any vaginal bleeding must be reported. |
| Ovarian suppression, GnRH-agonist class | Added for pre-menopausal women so that an aromatase-inhibitor-class tablet can work. Sometimes used alone in stromal tumours. | An injection every one to three months, and a full, abrupt menopause with the symptoms that come with it. |
| Selective oestrogen-receptor degrader class | Occasionally used in receptor-positive recurrent disease after other hormone options, on the strength of small studies rather than large trials. | An injection given at the clinic rather than a tablet, usually monthly, with injection-site soreness and menopausal effects. |
| Progestin class | An older option, still used occasionally in stromal tumours, and where appetite and weight loss are a problem alongside the cancer. | Tablets. Weight gain, fluid retention and a raised clot risk are the trade-offs, which is why it is now used selectively. |
*Nothing in this table is a recommendation for an individual. Which class suits you is decided from your pathology, your menopausal status and your other conditions — book a free consultation to have that worked through properly.
Two questions bring most women to this page. Either hormone therapy has been suggested and they want to know whether a tablet can really be enough, or it has never been mentioned and they have since read that their subtype might respond to it. Both are fair questions, and both take longer to answer than a follow-up slot allows.
Your first consultation at CION is free and runs to about 45 minutes. Bring the pathology report, the last scan, your CA-125 values and any receptor staining. What usually needs unpicking is specific: whether your tumour is genuinely one of the hormone-sensitive types or simply stains positive, whether you are post-menopausal enough for an aromatase-inhibitor-class tablet to work, and whether hormone therapy is the right next step or a way of postponing treatment you will need anyway. Every case is discussed at a tumour board rather than decided by one doctor.
It is worth being clear about who does what. Hormone therapy, chemotherapy and maintenance treatment are prescribed and monitored in-house at CION, across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Cytoreductive and staging surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed. For a low-grade serous or stromal tumour that ordering matters, because surgery usually comes first and the hormone tablet follows it.
On cost: hormone therapy is among the less expensive treatments in oncology, and it is taken for a long time, so what people want is the monthly figure with the monitoring costs alongside it. We put that in writing before treatment starts. Ask for a cost estimation at your first visit, or read our overview of ovarian cancer treatment in Hyderabad first.
Free and unhurried. Long enough to establish whether your tumour is one of the types this treatment genuinely helps, rather than assuming it from a receptor result.
Medical oncology, pathology and imaging review the subtype together — which matters most in the uncommon tumours where hormone therapy is used.
The tablet, the CA-125 checks, the scans and the bone-density monitoring, at whichever of our 35+ centres is closest to you.
A treatment taken for years deserves a written estimate before it begins. Decisions for healing, not billing — including the decision not to start it.
*Hormone therapy suits a minority of ovarian cancers and is not offered on request. Whether it suits you depends on your tumour type, your pathology and your menopausal status — book a free consultation to have that assessed.
For most ovarian cancers, no. For a specific minority, it works well. The tumours that respond are the ones genuinely driven by oestrogen: low-grade serous carcinoma, and the sex cord-stromal tumours such as adult granulosa cell tumour. In those, an anti-oestrogen tablet can hold disease still for a long time, and in low-grade serous it is one of the better options precisely because that subtype responds poorly to chemotherapy. In high-grade serous carcinoma, which is the commonest ovarian cancer, hormone therapy produces few useful responses and is not a substitute for surgery and platinum-based chemotherapy. So the honest answer depends entirely on which tumour you have, which is why the pathology report matters more here than almost anywhere else.
Three situations. First, low-grade serous carcinoma of the ovary or peritoneum, where an anti-oestrogen tablet is used as maintenance after surgery and chemotherapy, or as treatment when disease recurs. Second, sex cord-stromal tumours, particularly adult granulosa cell tumour, which arise from the ovary's hormone-producing tissue and can recur many years after the original surgery. Third, and more debatably, slowly growing receptor-positive recurrence of high-grade disease, where a break from chemotherapy is the priority and the disease is low in volume and causing few symptoms. Outside those three, hormone therapy is rarely the right choice, and being offered it instead of chemotherapy for newly diagnosed high-grade serous cancer is worth a second opinion.
Not necessarily, and this is the biggest misunderstanding on the subject. Receptor staining is done by immunohistochemistry on the tumour removed at surgery, and in breast cancer it predicts response to anti-hormone treatment reasonably well. In ovarian cancer it does not. Many high-grade serous tumours stain positive and still do not respond, because their growth is driven by genomic instability rather than by hormone signalling. A receptor-negative result is more useful than a positive one: it makes hormone therapy very unlikely to help, and spares you months of a treatment that would not have worked. What carries the most weight in the decision is the tumour type itself, not the percentage printed on the report.
No, and the two do opposite things. Hormone replacement therapy is given to a woman whose ovaries have been removed, to replace the oestrogen she has suddenly lost and to settle hot flushes, sleep and bone loss. Hormone therapy for cancer removes or blocks oestrogen, because a tumour is using it to grow. The same word covers both, which causes real confusion in clinic. Whether HRT is safe after ovarian cancer is a separate question with a different answer for different tumour types and ages, and it should be settled with your oncologist rather than by a general rule. Nobody should start or stop either treatment on the basis of a search result.
The effects are menopausal rather than those of chemotherapy. On the aromatase-inhibitor class, expect hot flushes, joint stiffness that is worst in the mornings, vaginal dryness and, over years, thinning bone, which is why a bone-density scan with calcium and vitamin D goes alongside it. On the SERM class, hot flushes, a small increase in clot risk, and thickening of the womb lining, so any vaginal bleeding must be reported. There is no hair loss and no drop in blood counts. Treatment usually continues for as long as it is working and tolerated, which can be years, with scans and CA-125 every few months. Tell your team about side effects rather than stopping the tablet quietly.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers hormone therapy, chemotherapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing where the diagnosis or family history warrants it. Cytoreductive and staging surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed, and we say so upfront rather than leaving it to be discovered later. Every case is reviewed at a tumour board, and the expected cost of treatment is put in writing before it begins.